“Tissue Eosinophil Counts as Predictors of Infliximab Response in Pediatric Inflammatory Bowel Disease: A Retrospective Nested Case Control Study”
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Infliximab is an effective therapy for pediatric inflammatory bowel disease (IBD), but a substantial proportion of patients experience primary non-response or relapse. Tissue eosinophilia has been implicated in treatment resistance, yet its predictive value in pediatric populations remains unclear.
Methods
We conducted a retrospective nested case–control study including 80 pediatric IBD patients treated with infliximab at CHU Sainte-Justine between 2014 and 2023 Relapse cases (n = 42) were defined by an increase in the short Pediatric Crohn’s Disease Activity Index (sPCDAI) ≥10, and compared with non-relapse controls (n = 38). Tissue eosinophil counts were quantified from diagnostic biopsies by blinded reviewers. Primary non-response was defined as a lack of clinical improvement before treatment change. Logistic regression and receiver operating characteristic (ROC) analyses were performed to assess associations between eosinophil counts and treatment outcomes.
Results
80 patients were included in the study. Median age at diagnosis was 14.4 years [Q1-Q3 (first quarter – third quarter) 12.35 – 16.00]. 40 patients had a diagnosis of ulcerative colitis (UC, 50%) and the other half had a diagnosis of Crohn’s disease (CD). Baseline eosinophil counts were not associated with subsequent relapse (odds ratio [OR] 1.02, 95% CI 0.98–1.06, p = 0.31), and ROC analysis demonstrated poor discrimination (AUC 0.57). In contrast, higher eosinophil counts were associated with primary non-response in ulcerative colitis patients (OR 1.08, 95% CI 1.01–1.16, p = 0.03). A cutoff of a median of ≥ 36 eosinophils per high-power field among all segments yielded 85% sensitivity and 80% specificity for predicting primary non-response (AUC 0.82).
Conclusion
Tissue eosinophil counts do not predict relapse in pediatric IBD patients treated with infliximab. However, elevated counts may identify ulcerative colitis patients at risk of primary non-response, suggesting a role for histological stratification in guiding the selection of biologics. Prospective validation in larger cohorts is warranted.
